Information Provided By:
Fly News Breaks for June 12, 2017
VICL
Jun 12, 2017 | 07:05 EDT
Rodman & Renshaw analyst Raghuram Selvaraju assumed coverage of Vical with a Buy rating and $9 price target. Vical continues to trade at a market cap below the most recently reported cash position despite its "diversified pipeline of clinical-stage assets," the analyst writes.
News For VICL From the Last 2 Days
There are no results for your query VICL